Zevra Therapeutics (ZVRA) Total Debt (2014 - 2025)

Zevra Therapeutics (ZVRA) has 8 years of Total Debt data on file, last reported at $61.9 million in Q4 2025.

• Quarterly Total Debt rose 4.07% year-over-year to $61.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $61.9 million (up 4.07% YoY) and the FY2025 annual result came in at $61.9 million, up 4.07% from the prior year.
• Total Debt rose to $61.9 million in Q4 2025, from $61.3 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $61.9 million in Q4 2025 to a low of $781000.0 in Q1 2021.
• A 5-year average of $43.6 million and a median of $58.3 million in 2024 frame the typical range for Total Debt.
• Annual changes were most pronounced in 2024 — Total Debt surged 193.78% — and 2025, when it gained 4.05%.
• Tracing ZVRA's Total Debt over 5 years: stood at $781000.0 in 2021, then surged by 1538.92% to $12.8 million in 2022, then soared by 234.11% to $42.8 million in 2023, then jumped by 39.14% to $59.5 million in 2024, then increased by 4.07% to $61.9 million in 2025.
• The last three Total Debt figures came in at $61.9 million (Q4 2025), $61.3 million (Q3 2025), and $60.7 million (Q2 2025), per Business Quant data.